Beijing, Aug 25, 2026 — China’s National Medical Products Administration (NMPA) suspended the import, sale, and use of three medical devices from U.S.-based Avinger, Inc. after the company failed to submit required documentation for an overseas inspection, marking a rare enforcement action against a foreign manufacturer for procedural non-compliance.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | National Medical Products Administration (NMPA) |
| Announcement | 2026 No. 80 |
| Target company | Avinger, Inc. (United States) |
| Effective date | Aug 25, 2026 |
| Legal basis | Provisions for Overseas Inspections of Drugs and Medical Devices, Article 28; Medical Device Supervision and Administration Regulations |
| Violation | Failure to submit power of attorney, product information forms, and site master files within required timeframe |
| Finding | Non-compliance with China’s Medical Device Production Quality Management Specification (GMP) |
Affected Products
| Product | Registration No. | Description |
|---|---|---|
| Pantheris Catheter | 国械注进20263010082 | Single-use peripheral vascular plaque resection catheter |
| Pantheris SV Catheter | 国械注进20253010610 | Single-use peripheral vascular plaque resection catheter |
| Lightbox 3 OCT Imaging Console | 国械注进20263010131 | Intravascular optical coherence tomography and power control device |
Enforcement Rationale
Under the NMPA’s 2026 overseas inspection plan, regulators scheduled an on-site review of Avinger’s manufacturing and quality systems. Avinger did not provide the mandated authorization letter, product status documentation, or site master file within the stipulated deadline. Pursuant to Article 28 of the overseas inspection regulations, the NMPA classified the deficiency as a failure to meet China’s medical device GMP standards, triggering an immediate suspension of all commercial activities for the three registered products.
Market Impact Analysis
The suspension halts Avinger’s commercial access to China’s market for its peripheral vascular and intravascular imaging portfolio. The Pantheris catheter line, used in peripheral artery disease interventions, and the Lightbox 3 OCT console, used for real-time intravascular imaging, are now barred from importation, distribution, and clinical use nationwide. For Chinese hospitals and distributors, the ban creates an immediate supply gap in peripheral atherectomy and OCT-guided vascular procedures, potentially shifting demand to competing devices from domestic or other international manufacturers.
The enforcement signals heightened NMPA willingness to invoke suspension powers for procedural lapses, not just product quality failures. By acting on documentation deficiencies rather than clinical adverse events, regulators are raising the compliance bar for foreign manufacturers navigating China’s overseas inspection regime.
Forward-Looking Statement
Industry analysts expect Avinger to face a lengthy reinstatement process requiring full documentation submission, followed by a rescheduled inspection and potential corrective action verification. The case is likely to prompt other U.S. and European device makers to audit their China regulatory file readiness, particularly authorization letters and site master files, ahead of scheduled 2026 overseas inspections. With Beijing intensifying scrutiny of imported medical devices, manufacturers with pending NMPA registrations should treat documentation compliance as a critical path item to avoid similar market access disruptions.-China Health Reform Pulse
For detailed implementation guidelines and the full list of approved products, refer to the official announcements from the Guangdong Provincial Medical Device Exchange Center.
Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20260825165610199.html